All lobbying filings

MARSHALL & POPP, LLC

MARSHALL & POPP, LLC filed a Q1 report for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES on April 21, 2025, reporting $40,000 in lobbying income.

Lobbying for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES · Pharmaceuticals.

All filings by MARSHALL & POPP, LLC · Everything JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Income

$40,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 2

HAZEN CLAY MARSHALL

Previously held: Policy Director-Senate Majority Leader Mitch McConnell; Staff Director/Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
MONICA POPP

Previously held: Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 946, Orphan Cures Act; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids. H.R.946 - ORPHAN Cures Act.

Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Bills named in this filing 4

H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 946
ORPHAN Cures Act
H. Con. Res. 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
S. Con. Res. 7
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.